| Autor: |
Hampson RJ; Thelial Technologies S.A., Lisbon, Portugal. rhampson@thelial.com, Wyatt MD |
| Jazyk: |
angličtina |
| Zdroj: |
Recent patents on endocrine, metabolic & immune drug discovery [Recent Pat Endocr Metab Immune Drug Discov] 2011 Sep; Vol. 5 (3), pp. 183-91. |
| DOI: |
10.2174/187221411797265944 |
| Abstrakt: |
Discovery of new cancer drugs is important for the improvement of disease treatment and management. In addition to the clear medical needs there are also economic considerations: Much drug discovery is performed in the private sector. The high cost of some drug treatments, which can run to tens of thousands of US$ per patient for single courses of therapy has led to the perception of high profitability in the industry. But drug discovery and development is a very expensive and lengthy process, with an ongoing trend of fewer drugs brought to market per dollar invested in R&D Biochemical-based in vitro screens for hosts of targets have produced early stage drug candidates and led to drugs reaching the market, but there remains a great need to evaluate in vivo efficacy, toxicity and potential off-target effects as early as possible in the discovery process. Using whole organisms much earlier in cancer (and other) drug discovery is a potential approach to improve R&D productivity. Here, we provide an overview of recent patenting activity and take a brief look at possible new developments in the field. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
